Exploring the Promise of At-Home Neuromodulation for Mood Disorders
Transcranial magnetic stimulation (TMS) has long been a beacon of hope for individuals battling major depressive disorder (MDD), especially when traditional treatments fall short. But now, a new wave of innovation—at-home single-pulse TMS (sTMS)—is reshaping the way we approach mood disorders and post-traumatic stress disorder (PTSD).
At eNeura, we’re at the forefront of this transformation.
The Mental Health Crisis: A Call for Accessible Innovation
Depression affects over 21 million Americans each year. For veterans, first responders, and trauma survivors, the burden is even greater, with PTSD and depression frequently coexisting and resistant to conventional care.
While antidepressants and therapy remain the standard of care, not every patient responds to them—and side effects, cost, or stigma can be barriers to long-term success.
That’s where neuromodulation enters the conversation.
What is TMS, and How Does It Help Mood Disorders?
TMS is a non-invasive brain stimulation therapy that uses magnetic fields to modulate neural activity in targeted brain regions. For depression, the focus is typically the left dorsolateral prefrontal cortex (DLPFC)—a region associated with emotion regulation, motivation, and executive function.
When stimulated repeatedly over time, this area can experience functional rebalancing, improving mood and cognitive control.
But most TMS systems require patients to attend in-clinic sessions 5 days a week for 4–6 weeks. This limits access, especially for rural populations, caregivers, and working individuals.
How Is eNeura’s sTMS Different?
Unlike traditional repetitive TMS (rTMS) systems used in clinics, eNeura’s sTMS delivers a gentle, single magnetic pulse to the back of the head (targeting the occipital cortex) from the comfort of home.
Emerging evidence and field experience show that this stimulation may regulate multiple neural networks, including those involved in mood, attention, and sensory processing.
Our device is:
- Prescription-based and FDA-cleared for migraine
- Safe for use in adolescents and adults
- Being evaluated for Breakthrough Device Designation for MDD
- Actively used in veteran-focused clinical initiatives, including dual diagnosis patients with migraine + PTSD or depression
Why This Matters for Dual Diagnosis and PTSD
A large percentage of patients with chronic migraine also suffer from mood disorders—and vice versa. This bidirectional relationship creates a clinical challenge: treating one often requires addressing both.
For veterans, this challenge is even more urgent. Traditional PTSD and depression treatments may not work, may take months to show results, or may not be tolerated.
sTMS offers:
- Drug-free symptom relief
- Home-based convenience that respects privacy and dignity
- Immediate integration with digital tracking tools for mood, sleep, and migraine symptoms
Potential use in combination protocols for mood + migraine (and beyond)
Looking Ahead: Clinical Research & FDA Pathways
eNeura is currently collaborating with mental health leaders to evaluate sTMS for:
- Major Depressive Disorder (MDD)
- PTSD
- Comorbid migraine and mood disorders
- Menstrual and hormonal mood syndromes linked to sensory hypersensitivity
We’re also actively pursuing FDA Breakthrough Device Designation to accelerate approval pathways and increase access through insurance reimbursement.
Empowering Mental Wellness, One Pulse at a Time
The future of mental health care is personalized, accessible, and multidimensional. We believe at-home sTMS represents a critical tool in that future—especially for those who’ve struggled with traditional treatments.
Whether you’re a veteran, a caregiver, or a provider looking for non-invasive solutions, the frontier of mental wellness is expanding. And eNeura is here to lead the way.
